• Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 common shares on October 19, 2026.
• The sale price was $38.4684 per share.
• Collins also exercised stock options for 5,000 common shares at $2.48 per share on the same date.
• Following the transactions, she directly held 25,000 common shares and 101,268 stock options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000014), on October 21, 2026, and is solely responsible for the information contained therein.